Latigo is a clinical-stage biopharmaceutical company developing non-opioid pain medicines. The company focuses on inhibiting Nav1.8, a voltage-gated sodium channel that transmits pain signals without causing addiction. Latigo currently has no approved products and generates no revenue. Its lead candidate, LTG-001, is an oral inhibitor for moderate to severe acute pain. In a Phase 2/3 trial, LTG-001 achieved greater pain reduction and faster relief than the opioid Vicodin. Latigo plans to initiate two additional Phase 3 trials in H2 2026 to support an NDA submission. The company's second clinical candidate, LTG-321, is a high-potency inhibitor for chronic musculoskeletal pain currently in a Phase 2 trial for osteoarthritis. A third candidate, LTG-418, is in preclinical development for delivery through alternative routes like gels, patches, and inhalers. Latigo is a pre-commercial business that funds operations through capital raises to support intensive R&D and clinical trial costs. Upon potential regulatory approval, Latigo intends to commercialize its products directly in the U.S. by building a sales force targeting surgeons, emergency physicians, and pain specialists. Latigo expects its current capital to fund operations into the second half of 2028.